Global Bispecific Antibody Therapeutics Market, 2017-2030 - Overall Pipeline Comprises of 200+ Molecules
DUBLIN, October 11, 2017 /PRNewswire/ --
The "Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030" report has been added to Research and Markets' offering.
The Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030' report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an elaborate discussion on the future potential of this upcoming market.
The field has captured the interest of several drug developers, including both small and large companies. As indicated before, the applicability of these engineered biomolecules is vast. Presently, only one bispecific antibody, BLINCYTO (2014), is available for therapeutic use. However, the development pipeline of bispecific antibody based drugs has several promising candidates that are likely to result in commercial success stories in the foreseen future.
The overall pipeline comprises of over 200 molecules that are under development for the treatment of various disease indications across different therapeutic areas, including oncology, autoimmune disorders and infectious diseases. Of these, more than 60 molecules are currently under clinical evaluation, while over 140 product candidates are in the discovery / preclinical stages.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2017-2030.
The research, analysis and insights presented in this report include potential sales of bispecific antibody therapeutics that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel bispecific antibody therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Jane Dancer (CBO, F-star), Ludge Groe-Hovest (Founder and CSO, Synimmune), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. Bispecific Antibody Therapeutics: Technology Platforms
6. Drug Profiles
7. Market Forecast And Opportunity Analysis
8. Partnerships And Collaborations
9. Key Insights
10. Case Study: Life Cycle Management Strategies
11. Case Study: Promotional/Marketing Strategies
12. SWOT Analysis
13. Conclusion
14. Interview Transcripts
15. Appendix 1: Tabulated Data
16. Appendix 2: List Of Companies And Organizations
Companies Mentioned
- Abbott
- AbbVie
- AbCheck
- AbClon
- Ablynx
- AbMed (a subsidiary of Abpro)
- Abpro
- Abzena
- Adimab
- Aduro Biotech
- Advagene Biopharma
- Advaxis Immunotherapies
- Affimed
- Agenus
- Ajou University, South Korea
- Albert Einstein College of Medicine, US
- Alexo Therapeutics
- Alissa Pharma
- Alligator Bioscience
- Alnylam Pharmaceuticals
- Ambrx
- Amgen
- Amphivena Therapeutics
- AnaptysBio
- AP Biosciences
- Aptevo Therapeutics
- ARIAD Pharmaceuticals
- Arrowhead Pharmaceuticals
- AstraZeneca
- Atlante Biotech
- Avillion
- Balgrist University Hospital, Switzerland
- Baliopharm (acquired by Alvotech)
- Barbara Ann Karmanos Cancer Institute, US
- Baxalta
- Bayer
- Benhealth Biopharmaceutical
- Beth Israel Deaconess Medical Center, US
- BIOCAD
- Biocells (Beijing) Biotech
- Biogen
- BioInvent International
- BioLineRx
- BIOMUNEX Pharmaceuticals
- BioNovion (acquired by Aduro Biotech)
- BioNTech
- Biotecnol
- Bioverativ
- Boehringer Ingelheim
- California Institute for Biomedical Research, US
- Catalent Biologics
- Celgene
- Cepheid
- ChemPartner
- Chugai Pharmaceutical
- CMC Biologics
- Columbia University, US
- Cormorant Pharmaceuticals (acquired by Bristol-Myers Squibb)
- Covagen (acquired by Cilag)
- Creative Biolabs
- CytomX Therapeutics
- Daiichi Sankyo
- Denali Therapeutics
- Duke Neurosurgery, US
- Dutalys
- Eddingpharm
- Eli Lilly
- Emergent BioSolutions
- EnGeneIC
- EngMab (acquired by Celgene)
- EpimAb Biotherapeutics
- Fabion Pharmaceuticals
- Fidelity Management & Research
- Five Prime Therapeutics
- Flatiron Health
- Foundation Medicine
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany
- Fresenius Biotech
- F-star
- Fudan University, China
- Fusion Antibodies
- FZata
- Ganymed Pharmaceuticals (acquired by Astellas Pharma)
- Genentech
- General Electric (GE)
- Genmab
- Genzyme
- German Cancer Research Center (DKFZ), Germany
- Gilead Sciences
- Glaxo Smith Kline (GSK)
- Glenmark Pharmaceuticals
- Goodwin Biotechnology
- Guangdong Medical University, China
- Gustave Roussy
- Hanmi Pharmaceutical
- Hanwha Chemical R&D Center, Korea
- Harvard University, US
- Henlix Biotech
- Humabs BioMed
- Human Longevity
- i2 Pharmaceuticals
- IGM Biosciences
- Immatics Biotechnologies
- Immune Pharmaceuticals
- Immunomedics
- Imunexus
- Incyte
- InflaRx
- Innate Pharma
- Innovent Biologics
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland
- Institute for Research in Biomedicine (IRB) Barcelona, Spain
- Intarcia Therapeutics
- Ipsen
- Janssen Biotech
- Janssen-Cilag
- JW Pharmaceutical
- Kairos Therapeutics
- Kymab
- Kyowa Hakko Kirin
- Leica Biosystems
- Leland Stanford Junior University, US
- Leukemia and Lymphoma Society, US
- Ligand Pharmaceuticals
- LINDIS Biotech
- MacroGenics
- Masonic Cancer Center, US
- Massachusetts General Hospital, US
- Massachusetts Institute of Technology (MIT), US
- MediaPharma
- MedImmune
- Memorial Sloan Kettering Cancer Center, US
- Merck
- Merrimack Pharmaceuticals
- Merus
- Micromet
- Mitsubishi Tanabe Pharma
- MorphoSys
- Nanjing Abingen
- Nanjing Medical University, China
- National Cancer Institute (NCI), US
- Neovii Biotech
- Northeast Agricultural University, China
- Novartis
- Novimmune
- Novo Nordisk
- Numab
- OcellO
- OncoMed Pharmaceuticals
- Ono Pharmaceutical
- Oxis Biotech
- Pfizer
- PharmAbcine
- Pharmacyclics
- Pieris Pharmaceuticals
- Regeneron Pharmaceuticals
- RenMin Hospital, Wuhan University, China
- Roche
- Samsung Advanced Institute of Technology (SAIT), South Korea
- Sanofi
- SATT Sud-Est
- SBI Pharmaceuticals
- Sea Lane Biotechnologies
- Second Military Medical University, Shanghai
- Selexis
- Servier
- Shire
- SiteOne Therapeutics
- Spectrum Pharmaceuticals
- Stanford University, US
- Stemcentrx
- Sun Yat-sen University, China
- Sutro Biopharma
- Synergys
- Synimmune
- Systimmune
- Taisho Pharmaceutical
- Takeda Pharmaceutical
- Teijin Pharma
- TESARO
- The Scripps Research Institute, US
- The University of Texas MD Anderson Cancer Center, US
- Tianjin Nankai Hospital, China
- TriOn Pharma
- University of California, Los Angeles (UCLA), US
- University of Cologne, Germany
- University of Groningen, Netherlands
- University of Minnesota, US
- University of Munich, Germany
- University of Virginia, US
- Van Herk Investments
- Vanderbilt Vaccine Center, US
- Vrije Universiteit Brussel, Belgium
- Wal-Mart
- Warburg Pincus
- Wellcome Trust Sanger Institute, England
- Wuhan YZY Biopharma
- WuXi Biologics
- Xencor
- Y-mAbs Therapeutics
- Zhejiang Hisun Pharmaceutical
- Zymeworks
- Zyngenia
For more information about this report visit https://www.researchandmarkets.com/research/664rwb/bispecific
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article